<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141218020364N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-03-03</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Limberg Flap and Karydakis Flap Surgery For Pilonidal Sinus Disease</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Limberg Flap and Karydakis Flap Surgery in Pilonidal Sinus Disease</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29482</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random drawing of sealed envelopes (Computer-based table of randomization ), Blinding description: The study participants had known two types of common pilonidal off-midline flap surgery treatment, But due to the dressing on the wound, they were not aware of the type of treatment we were used for them. The observer who completed the questionnaire did know the study groups. The original researcher (surgeon) was aware of the study groups. The data analyzer was not known from the study groups. The safety committee and data monitoring were aware of the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pilonidal Sinus Disease.</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group: The Limberg flap (LF) group, Rhomboid excision was performed, the lower end being 2 cm lateral to the midline and covering the whole area where the sinus spread. Using electrocautery, hemostasis was provided. In order to ensure tension-free repair, the flap was released at the bottom including gluteal fascia and then slid to medial in order to cover the defect. A suction drain was applied to the region in all patients. The subcutaneous tissue was closed with 2-fold 2/0 polyglactin suture (Ethicon US, LLC, Cincinnati, Ohio), and the skin was closed with 3/0 polypropylene (Ethicon US, LLC) mattress suture. When the drain amount fell below 40 mL/d, it was removed. Intervention 2: Second Intervention group: The Karydakis Flap (LF) group, In this group an asymmetrical elliptic excision was done, lower and upper ends being located at approximately 2 cm lateral to the natal cleft, and all defective tissues were removed until reaching to the healthy borders. After that, the medical wound edge was mobilized, and the flap was slid by suturing to the fascia and skin suitable wound layers on the lateral wound edge corresponding to one another. The subcutaneous tissue was closed with 2-fold 2/0 polyglactin suture, and the skin was closed with 3/0 polypropylene mattress suture. In all patients, a suction drain was applied to the region. When the drain amount fell below 40 mL/d, it was removed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohhammad Yasin Karami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faghighi Hospital</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>987441756965</zip>
        <telephone>+98 71 3839 1385</telephone>
        <email>karamiy@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohhammad Yasin Karami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faghighi Hospital</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7441756965</zip>
        <telephone>+98 71 3233 0724</telephone>
        <email>karamiy@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Intergluteal Pilonidal Disease
Age more than 15 year
Age less than 65 year</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Elderly patients with co-morbidity diseases
Scars from previous pilonidal surgery
Abscess presentation
Patients with diabetes mellitus, immunodeficiency, neurological disorder
Drug addiction
Alcoholism
American Society of Anesthesiologists physical status classification 3–4
Those who are under 15 and over 65
Those whose pilonidal sinus orifice was located away more than 3 cm</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L05.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pilonidal cyst and sinus without abscess</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group: The Limberg flap (LF) group, Rhomboid excision was performed, the lower end being 2 cm lateral to the midline and covering the whole area where the sinus spread. Using electrocautery, hemostasis was provided. In order to ensure tension-free repair, the flap was released at the bottom including gluteal fascia and then slid to medial in order to cover the defect. A suction drain was applied to the region in all patients. The subcutaneous tissue was closed with 2-fold 2/0 polyglactin suture (Ethicon US, LLC, Cincinnati, Ohio), and the skin was closed with 3/0 polypropylene (Ethicon US, LLC) mattress suture. When the drain amount fell below 40 mL/d, it was removed.</i_keyword>
      <i_keyword>Second Intervention group: The Karydakis Flap (LF) group, In this group an asymmetrical elliptic excision was done, lower and upper ends being located at approximately 2 cm lateral to the natal cleft, and all defective tissues were removed until reaching to the healthy borders. After that, the medical wound edge was mobilized, and the flap was slid by suturing to the fascia and skin suitable wound layers on the lateral wound edge corresponding to one another. The subcutaneous tissue was closed with 2-fold 2/0 polyglactin suture, and the skin was closed with 3/0 polypropylene mattress suture. In all patients, a suction drain was applied to the region. When the drain amount fell below 40 mL/d, it was removed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Patients were visited weekly for the first month and subsequently every 3 months for the first 6 months. Method of measurement: Visual Analogue Score.</prim_outcome>
      <prim_outcome>Duration of Surgery. Timepoint: During operation. Method of measurement: Evaluated by Surgeon.</prim_outcome>
      <prim_outcome>Satisfaction. Timepoint: Patients were visited weekly for the first month and subsequently every 3 months for the first 6 months. Method of measurement: Visual Analogue Score.</prim_outcome>
      <prim_outcome>Complication. Timepoint: Patients were visited weekly for the first month and subsequently every 3 months for the first 6 months. Method of measurement: Direct supervision by the surgeon.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Recurrence Rate. Timepoint: Patients were visited weekly for the first month and subsequently every 3 months for the first 6 months. Method of measurement: Follow up by surgeon.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-10-19</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Valie Asr highway Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
